Zheng X, Zheng Y, Zhang Y, Xie J, Teng X, Bi K
Infect Agent Cancer. 2025; 20(1):3.
PMID: 39844250
PMC: 11756112.
DOI: 10.1186/s13027-024-00627-x.
Lin Y, Zheng Y
J Mol Biol. 2024; 437(3):168919.
PMID: 39708912
PMC: 11757035.
DOI: 10.1016/j.jmb.2024.168919.
Liu G, Dong B, Devanarayana S, Chen R, Liu Q
Front Immunol. 2024; 15:1479230.
PMID: 39664395
PMC: 11631737.
DOI: 10.3389/fimmu.2024.1479230.
Jung J
Case Rep Oncol. 2024; 17(1):973-981.
PMID: 39474534
PMC: 11521470.
DOI: 10.1159/000540784.
Iqbal J, Inghirami G, Chan W
Blood. 2024; 144(18):1873-1886.
PMID: 39213420
PMC: 11551850.
DOI: 10.1182/blood.2023021787.
Tumor-derived RHOA mutants interact with effectors in the GDP-bound state.
Lin Y, Ramelot T, Senyuz S, Gursoy A, Jang H, Nussinov R
Nat Commun. 2024; 15(1):7176.
PMID: 39169042
PMC: 11339415.
DOI: 10.1038/s41467-024-51445-z.
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine.
Hu L, Zhang X, Zang S
Cancer Biol Med. 2024; 21(9).
PMID: 39119774
PMC: 11414223.
DOI: 10.20892/j.issn.2095-3941.2024.0132.
RHOF activation of AKT/β-catenin signaling pathway drives acute myeloid leukemia progression and chemotherapy resistance.
Wen X, Li P, Ma Y, Wang D, Jia R, Xia Y
iScience. 2024; 27(7):110221.
PMID: 39021805
PMC: 11253531.
DOI: 10.1016/j.isci.2024.110221.
Single-cell landscape reveals the immune heterogeneity of bone marrow involvement in peripheral T-cell lymphoma.
Liu J, Xia B, Jiang X, Cao L, Xi Z, Liang L
Cancer Sci. 2024; 115(8):2540-2552.
PMID: 38845192
PMC: 11309951.
DOI: 10.1111/cas.16227.
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.
Chang E, Tan Y, Chan J
J Hematol Oncol. 2024; 17(1):38.
PMID: 38824603
PMC: 11144347.
DOI: 10.1186/s13045-024-01560-7.
Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report.
Khatri J, Tahboub I, Anwar K, Masoudi M, Graffeo V, Jamil M
J Investig Med High Impact Case Rep. 2024; 12:23247096241231645.
PMID: 38761096
PMC: 11102676.
DOI: 10.1177/23247096241231645.
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.
Huang Z, Fu Y, Yang H, Zhou Y, Shi M, Li Q
Mol Cancer. 2024; 23(1):36.
PMID: 38365716
PMC: 10874034.
DOI: 10.1186/s12943-024-01947-7.
Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
Han B, Lim S, Yim J, Song Y, Koh J, Kim S
J Pathol Transl Med. 2024; 58(2):59-71.
PMID: 38247153
PMC: 10948251.
DOI: 10.4132/jptm.2024.01.04.
Recognizing puzzling PD1 + infiltrates in marginal zone lymphoma by integrating clonal and mutational findings: pitfalls in both nodal and transformed splenic cases.
Deng J, Cao Y, Diao X, Wu M, Li X, Shi Y
Diagn Pathol. 2023; 18(1):134.
PMID: 38082447
PMC: 10712042.
DOI: 10.1186/s13000-023-01422-9.
Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients.
Shi Y, Wang H, Liu Y, Long M, Ding N, Mi L
Chin J Cancer Res. 2023; 35(5):536-549.
PMID: 37969960
PMC: 10643336.
DOI: 10.21147/j.issn.1000-9604.2023.05.10.
TCR Pathway Mutations in Mature T Cell Lymphomas.
Zhang Y, Cheng K, Choi J
J Immunol. 2023; 211(10):1450-1458.
PMID: 37931208
PMC: 10715708.
DOI: 10.4049/jimmunol.2200682.
Biological insights into the role of TET2 in T cell lymphomas.
Carty S
Front Oncol. 2023; 13:1199108.
PMID: 37841428
PMC: 10570544.
DOI: 10.3389/fonc.2023.1199108.
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.
Zhang Q, Yin L, Lai Q, Zhao Y, Peng H
Clin Exp Med. 2023; 23(8):4219-4235.
PMID: 37759042
DOI: 10.1007/s10238-023-01197-9.
Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.
Yadav M, Uikey B, Rathore S, Gupta P, Kashyap D, Kumar C
Front Oncol. 2023; 13:1235711.
PMID: 37746258
PMC: 10513393.
DOI: 10.3389/fonc.2023.1235711.
How molecular advances may improve the diagnosis and management of PTCL patients.
Drieux F, Lemonnier F, Gaulard P
Front Oncol. 2023; 13:1202964.
PMID: 37427095
PMC: 10328093.
DOI: 10.3389/fonc.2023.1202964.